Sugi Predict

Sugi Predict / Compounds / SCHEMBL19782863

SCHEMBL19782863

SCHEMBL19782863

Cc1cc(OCCNC(=O)OC(C)(C)C)cc2sc(N)nc12

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 5/20 0.47
▸ CA1 P00915 5/20 0.47
▸ CA2 P00918 5/20 0.47
▸ CA9 Q16790 5/20 0.47
▸ HSD17B10 Q99714 1/20 0.41
▸ LCK P06239 1/20 0.40
▸ PDK2 Q15119 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ BRD4 O60885 3/20 0.39
▸ EGFR P00533 1/20 0.38
▸ ITK Q08881 1/20 0.38
▸ SIRT2 Q8IXJ6 1/20 0.36
▸ SIRT1 Q96EB6 1/20 0.36
▸ SIRT3 Q9NTG7 1/20 0.36
▸ STK17B O94768 1/20 0.35
▸ STK17A Q9UEE5 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189679 1.00 CA12 (0.47) CA12CA1CA2CA9HSD17B10
SCHEMBL19782871 0.88 CA12 (0.46) CA12CA1CA2CA9PDK2
SCHEMBL30189788 0.88 CA12 (0.46) CA12CA1CA2CA9PDK2
SCHEMBL30189776 0.88 CA12 (0.45) CA12CA1CA2CA9LCK
SCHEMBL21395510 0.88 CA12 (0.45) CA12CA1CA2CA9LCK
SCHEMBL30189761 0.87 CA12 (0.44) CA12CA1CA2CA9LCK
SCHEMBL19783354 0.87 CA12 (0.44) CA12CA1CA2CA9LCK
SCHEMBL30189719 0.87 CA12 (0.44) CA12CA1CA2CA9PDK2
SCHEMBL19782854 0.87 CA12 (0.44) CA12CA1CA2CA9PDK2
SCHEMBL19783605 0.81 IKBKB (0.42) CA12CA1CA2CA9PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 — — US disclosed
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 — — CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 — — US disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 — — US disclosed
EP-3484878-B1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-08-19 — — EP disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 — — US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 — — US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 CA12 3794/4885CA1 3155/4885CA2 2280/4885
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CA12 3728/4885CA1 2630/4885CA2 1774/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CA12 3794/4885CA1 3155/4885CA2 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.